1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 49, 09/Dec/2021
  4. Article
Research Open Access
Like 0
Download

Abstract

Background

People who inject drugs (PWID) are frequently incarcerated, which is associated with multiple negative health outcomes.

Aim

We aimed to estimate the associations between a history of incarceration and prevalence of HIV and HCV infection among PWID in Europe.

Methods

Aggregate data from PWID recruited in drug services (excluding prison services) or elsewhere in the community were reported by 17 of 30 countries (16 per virus) collaborating in a European drug monitoring system (2006–2020; n = 52,368 HIV+/−; n = 47,268 HCV+/−). Country-specific odds ratios (OR) and prevalence ratios (PR) were calculated from country totals of HIV and HCV antibody status and self-reported life-time incarceration history, and pooled using meta-analyses. Country-specific and overall population attributable risk (PAR) were estimated using pooled PR.

Results

Univariable HIV OR ranged between 0.73 and 6.37 (median: 2.1; pooled OR: 1.92; 95% CI: 1.52–2.42). Pooled PR was 1.66 (95% CI 1.38–1.98), giving a PAR of 25.8% (95% CI 16.7–34.0). Univariable anti-HCV OR ranged between 1.06 and 5.04 (median: 2.70; pooled OR: 2.51; 95% CI: 2.17–2.91). Pooled PR was 1.42 (95% CI: 1.28–1.58) and PAR 16.7% (95% CI: 11.8–21.7). Subgroup analyses showed differences in the OR for HCV by geographical region, with lower estimates in southern Europe.

Conclusion

In univariable analysis, a history of incarceration was associated with positive HIV and HCV serostatus among PWID in Europe. Applying the precautionary principle would suggest finding alternatives to incarceration of PWID and strengthening health and social services in prison and after release (‘throughcare’).

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.49.2002093
2021-12-09
2024-12-21
/content/10.2807/1560-7917.ES.2021.26.49.2002093
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/49/eurosurv-26-49-6.html?itemId=/content/10.2807/1560-7917.ES.2021.26.49.2002093&mimeType=html&fmt=ahah

References

  1. Dolan K, Khoei EM, Brentari C, Stevens A. Prisons and Drugs: A global review of incarceration, drug use and drug services. Oxford: The Beckley Foundation; 2007. Available from: https://www.beckleyfoundation.org/wp-content/uploads/2016/04/BF_Report_12.pdf
  2. World Health Organization Regional Office for Europe (WHO/Europe). Prisons and health. Copenhagen: WHO/Europe; 2014. Available from: http://www.euro.who.int/__data/assets/pdf_file/0005/249188/Prisons-and-Health.pdf?ua=1
  3. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192-207.  https://doi.org/10.1016/S2214-109X(17)30375-3  PMID: 29074409 
  4. Wood E, Werb D, Kazatchkine M, Kerr T, Hankins C, Gorna R, et al. Vienna Declaration: a call for evidence-based drug policies. Lancet. 2010;376(9738):310-2.  https://doi.org/10.1016/S0140-6736(10)60958-0  PMID: 20650517 
  5. Sugarman OK, Bachhuber MA, Wennerstrom A, Bruno T, Springgate BF. Interventions for incarcerated adults with opioid use disorder in the United States: A systematic review with a focus on social determinants of health. PLoS One. 2020;15(1):e0227968.  https://doi.org/10.1371/journal.pone.0227968  PMID: 31961908 
  6. Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089-102.  https://doi.org/10.1016/S0140-6736(16)30466-4  PMID: 27427453 
  7. Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18(12):1397-409.  https://doi.org/10.1016/S1473-3099(18)30469-9  PMID: 30385157 
  8. Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013;58(4):1215-24.  https://doi.org/10.1002/hep.26387  PMID: 23504650 
  9. Wirtz AL, Yeh PT, Flath NL, Beyrer C, Dolan K. HIV and viral hepatitis among imprisoned key populations. Epidemiol Rev. 2018;40(1):12-26.  https://doi.org/10.1093/epirev/mxy003  PMID: 29688317 
  10. Zlodre J, Fazel S. All-cause and external mortality in released prisoners: systematic review and meta-analysis. Am J Public Health. 2012;102(12):e67-75.  https://doi.org/10.2105/AJPH.2012.300764  PMID: 23078476 
  11. Merrall EL, Kariminia A, Binswanger IA, Hobbs MS, Farrell M, Marsden J, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105(9):1545-54.  https://doi.org/10.1111/j.1360-0443.2010.02990.x  PMID: 20579009 
  12. Degenhardt L, Larney S, Kimber J, Gisev N, Farrell M, Dobbins T, et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction. 2014;109(8):1306-17.  https://doi.org/10.1111/add.12536  PMID: 24612249 
  13. Strathdee SA, West BS, Reed E, Moazen B, Azim T, Dolan K. Substance Use and HIV among female sex workers and female prisoners: risk environments and implications for prevention, treatment, and policies. J Acquir Immune Defic Syndr. 2015;69(Suppl 2):S110-7.  https://doi.org/10.1097/QAI.0000000000000624  PMID: 25978477 
  14. Fuge TG, Tsourtos G, Miller ER. A systematic review and meta-analyses on initiation, adherence and outcomes of antiretroviral therapy in incarcerated people. PLoS One. 2020;15(5):e0233355.  https://doi.org/10.1371/journal.pone.0233355  PMID: 32421754 
  15. Ickowicz S, Salleh NAM, Fairbairn N, Richardson L, Small W, Milloy MJ. criminal justice system involvement as a risk factor for detectable plasma hiv viral load in people who use illicit drugs: a longitudinal cohort study. AIDS Behav. 2019;23(9):2634-9.  https://doi.org/10.1007/s10461-019-02547-z  PMID: 31236749 
  16. Milloy MJ, Kerr T, Buxton J, Rhodes T, Guillemi S, Hogg R, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203(9):1215-21.  https://doi.org/10.1093/infdis/jir032  PMID: 21459814 
  17. Rich JD, Beckwith CG, Macmadu A, Marshall BDL, Brinkley-Rubinstein L, Amon JJ, et al. Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. Lancet. 2016;388(10049):1103-14.  https://doi.org/10.1016/S0140-6736(16)30379-8  PMID: 27427452 
  18. Semaille C, Le Strat Y, Chiron E, Chemlal K, Valantin MA, Serre P, et al. Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy. Euro Surveill. 2013;18(28):20524.  https://doi.org/10.2807/1560-7917.ES2013.18.28.20524  PMID: 23870097 
  19. Cunningham EB, Hajarizadeh B, Bretana NA, Amin J, Betz-Stablein B, Dore GJ, et al. Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study. J Viral Hepat. 2017;24(9):733-41.  https://doi.org/10.1111/jvh.12701  PMID: 28256027 
  20. Danis K, Doherty L, McCartney M, McCarrol J, Kennedy H. Hepatitis and HIV in Northern Ireland prisons: a cross-sectional study. Euro Surveill. 2007;12(1):3.  https://doi.org/10.2807/esm.12.01.00674-en  PMID: 27938649 
  21. Milloy MJ, Buxton J, Wood E, Li K, Montaner JS, Kerr T. Elevated HIV risk behaviour among recently incarcerated injection drug users in a Canadian setting: a longitudinal analysis. BMC Public Health. 2009;9(1):156.  https://doi.org/10.1186/1471-2458-9-156  PMID: 19473508 
  22. Werb D, Kerr T, Small W, Li K, Montaner J, Wood E. HIV risks associated with incarceration among injection drug users: implications for prison-based public health strategies. J Public Health (Oxf). 2008;30(2):126-32.  https://doi.org/10.1093/pubmed/fdn021  PMID: 18387974 
  23. Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, et al. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016;388(10050):1228-48.  https://doi.org/10.1016/S0140-6736(16)30856-X  PMID: 27427455 
  24. Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, Taylor A, et al. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction. 2017;112(7):1302-14.  https://doi.org/10.1111/add.13783  PMID: 28257600 
  25. Treloar C, McCredie L, Lloyd AR. The Prison Economy of Needles and Syringes: What Opportunities Exist for Blood Borne Virus Risk Reduction When Prices Are so High? PLoS One. 2016;11(9):e0162399. PMID: 27611849 
  26. Wood E, Li K, Small W, Montaner JS, Schechter MT, Kerr T. Recent incarceration independently associated with syringe sharing by injection drug users. Public Health Rep. 2005;120(2):150-6.  https://doi.org/10.1177/003335490512000208  PMID: 15842116 
  27. Michel L, Trouiller P, Chollet A, Molinier M, Duchesne L, Jauffret-Roustide M, ANRS-Coquelicot Study Group. Self-reported injection practices among people who use drugs in French prisons: Public health implications (ANRS-Coquelicot survey 2011-2013). Drug Alcohol Rev. 2018;37(Suppl 1):S268-76.  https://doi.org/10.1111/dar.12620  PMID: 29105203 
  28. Cepeda JA, Niccolai LM, Lyubimova A, Kershaw T, Levina O, Heimer R. High-risk behaviors after release from incarceration among people who inject drugs in St. Petersburg, Russia. Drug Alcohol Depend. 2015;147:196-202.  https://doi.org/10.1016/j.drugalcdep.2014.11.021  PMID: 25496706 
  29. Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison--a high risk of death for former inmates. N Engl J Med. 2007;356(2):157-65.  https://doi.org/10.1056/NEJMsa064115  PMID: 17215533 
  30. Kariminia A, Law MG, Butler TG, Corben SP, Levy MH, Kaldor JM, et al. Factors associated with mortality in a cohort of Australian prisoners. Eur J Epidemiol. 2007;22(7):417-28. https://doi.org/10.1007/s10654-007-9134-1  PMID: 17668280 
  31. Merrall EL, Kariminia A, Binswanger IA, Hobbs MS, Farrell M, Marsden J, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105(9):1545-54.  https://doi.org/10.1111/j.1360-0443.2010.02990.x  PMID: 20579009 
  32. Borquez A, Beletsky L, Nosyk B, Strathdee SA, Madrazo A, Abramovitz D, et al. The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study. Lancet Public Health. 2018;3(9):e429-37.  https://doi.org/10.1016/S2468-2667(18)30097-5  PMID: 30122559 
  33. Gassowski M, Nielsen S, Bannert N, Bock CT, Bremer V, Ross RS, et al. History of detention and the risk of hepatitis C among people who inject drugs in Germany. Int J Infect Dis. 2019;81:100-6.  https://doi.org/10.1016/j.ijid.2019.01.015  PMID: 30658167 
  34. Michel L, Lions C, Van Malderen S, Schiltz J, Vanderplasschen W, Holm K, et al. Insufficient access to harm reduction measures in prisons in 5 countries (PRIDE Europe): a shared European public health concern. BMC Public Health. 2015;15(1):1093.  https://doi.org/10.1186/s12889-015-2421-y  PMID: 26507505 
  35. Stöver H, Hariga F. Prison-based needle and syringe programmes (PNSP) – Still highly controversial after all these years. Drugs Educ Prev Policy. 2016;23(2):103-12.  https://doi.org/10.3109/09687637.2016.1148117 
  36. Kamarulzaman A, Reid SE, Schwitters A, Wiessing L, El-Bassel N, Dolan K, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet. 2016;388(10049):1115-26.  https://doi.org/10.1016/S0140-6736(16)30769-3  PMID: 27427456 
  37. Tarján A, Horváth G, Stöver H. European mapping of harm reduction interventions in prisons – revised version: July 2019. Frankfurt: Frankfurt University of Applied Sciences; 2019. Available from: https://www.researchgate.net/publication/335022280_European_Mapping_of_harm_reduction_interventions_in_prisons_-_Revised_version_July_2019
  38. Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376(9738):355-66.  https://doi.org/10.1016/S0140-6736(10)60832-X  PMID: 20650513 
  39. MacDonald M, Williams J, Kane D. Barriers to implementing throughcare for problematic drug users in European prisons. Int J Prison Health. 2012;8(2):68-84.  https://doi.org/10.1108/17449201211277192  PMID: 25758018 
  40. Stöver H, Jamin D, Sys O, Vanderplasschen W, Jauffret-Roustide M, Michel L, et al. Continuity of care for drug users in prisons and beyond in four European countries - Final report. Frankfurt: Frankfurt University of Applied Sciences; 2019. Available from: https://www.frankfurt-university.de/fileadmin/standard/Hochschule/Fachbereich_4/Forschung/ISFF/Forschungsprojekte/Abgeschlossene_Projekte/48h_out_finalreport_WP3_march2019.pdf
  41. Friedman SR, Cooper HL, Tempalski B, Keem M, Friedman R, Flom PL, et al. Relationships of deterrence and law enforcement to drug-related harms among drug injectors in US metropolitan areas. AIDS. 2006;20(1):93-9.  https://doi.org/10.1097/01.aids.0000196176.65551.a3  PMID: 16327324 
  42. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010;376(9737):268-84.  https://doi.org/10.1016/S0140-6736(10)60743-X  PMID: 20650523 
  43. Csete J, Kamarulzaman A, Kazatchkine M, Altice F, Balicki M, Buxton J, et al. Public health and international drug policy. Lancet. 2016;387(10026):1427-80.  https://doi.org/10.1016/S0140-6736(16)00619-X  PMID: 27021149 
  44. Strathdee SA, Beletsky L, Kerr T. HIV, drugs and the legal environment. Int J Drug Policy. 2015;26(Suppl 1):S27-32.  https://doi.org/10.1016/j.drugpo.2014.09.001  PMID: 25265900 
  45. Hurley R. How to save drug users’ lives. BMJ. 2019;366:l5050.  https://doi.org/10.1136/bmj.l5050  PMID: 21868460 
  46. Kruithof K, Davies M, Disley E, Strang L, Ito K. Study on alternatives to coercive sanctions as response to drug law offences and drug-related crimes. Brussels: European Commission; 2016. Available from: http://sisco.copolad.eu/web/uploads/documentos/PB_DGHOME_Publicacion_alternativas_encarcelamiento.pdf
  47. Gjersing L. Decriminalisation and possible impact on prison population and drug related problems. Session on Prison and drugs in Europe. Lisbon Addiction conference 2019; 23-25 October 2019, Lisbon, Portugal. Available from: https://www.lisbonaddictions.eu/lisbon-addictions-2019/presentations/decriminalisation-and-possible-impact-prison-population-and-drug-related-problems
  48. Hughes CE, Stevens A. The effects of the decriminalization of drug use in Portugal. Discussion paper. Oxford: The Beckley Foundation; 2007. Available from: https://kar.kent.ac.uk/13325/1/BFDPP_BP_14_EffectsOfDecriminalisation_EN.pdf.pdf
  49. Gonçalves R, Lourenço A, Silva SN. A social cost perspective in the wake of the Portuguese strategy for the fight against drugs. Int J Drug Policy. 2015;26(2):199-209.  https://doi.org/10.1016/j.drugpo.2014.08.017  PMID: 25265899 
  50. Tamhane AR, Westfall AO, Burkholder GA, Cutter GR. Prevalence odds ratio versus prevalence ratio: choice comes with consequences. Stat Med. 2016;35(30):5730-5.  https://doi.org/10.1002/sim.7059  PMID: 27460748 
  51. United Nations Statistics Division. Methodology - Standard country or area codes for statistical use (M49). New York: United Nations. [Accessed: 15 Aug 2020]. Available from: https://unstats.un.org/unsd/methodology/m49
  52. Institute for Crime & Justice Policy Research (ICPR). World prison brief. London: ICPR; 2020 [Accessed: 15 Aug 2020]. Available from: https://prisonstudies.org/world-prison-brief-data
  53. Dolan K, Kite B, Black E, Aceijas C, Stimson GV, Reference Group on HIV/AIDS Prevention and Care among Injecting Drug Users in Developing and Transitional Countries. HIV in prison in low-income and middle-income countries. Lancet Infect Dis. 2007;7(1):32-41.  https://doi.org/10.1016/S1473-3099(06)70685-5  PMID: 17182342 
  54. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Lithuania country drug report 2019. Lisbon: EMCDDA; 2019. Available from: https://www.emcdda.europa.eu/system/files/publications/11341/lithuania-cdr-2019_0.pdf
  55. Kivimets K, Uusküla A, Lazarus JV, Ott K. Hepatitis C seropositivity among newly incarcerated prisoners in Estonia: data analysis of electronic health records from 2014 to 2015. BMC Infect Dis. 2018;18(1):339.  https://doi.org/10.1186/s12879-018-3242-2  PMID: 30031373 
  56. Niculescu I, Paraschiv S, Paraskevis D, Abagiu A, Batan I, Banica L, et al. Recent HIV-1 outbreak among intravenous drug users in Romania: evidence for cocirculation of CRF14_BG and subtype F1 strains. AIDS Res Hum Retroviruses. 2015;31(5):488-95.  https://doi.org/10.1089/aid.2014.0189  PMID: 25369079 
  57. McAuley A, Palmateer NE, Goldberg DJ, Trayner KMA, Shepherd SJ, Gunson RN, et al. Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis. Lancet HIV. 2019;6(5):e315-24.  https://doi.org/10.1016/S2352-3018(19)30036-0  PMID: 30981674 
  58. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168(10):1099-109.  https://doi.org/10.1093/aje/kwn237  PMID: 18849303 
  59. Maher L, Chant K, Jalaludin B, Sargent P. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia. J Gastroenterol Hepatol. 2004;19(10):1114-20.  https://doi.org/10.1111/j.1440-1746.2004.03438.x  PMID: 15377287 
  60. Tyndall MW, Currie S, Spittal P, Li K, Wood E, O’Shaughnessy MV, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS. 2003;17(6):887-93.  https://doi.org/10.1097/00002030-200304110-00014  PMID: 12660536 
  61. Allen EJ, Palmateer NE, Hutchinson SJ, Cameron S, Goldberg DJ, Taylor A. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. Int J Drug Policy. 2012;23(5):346-52.  https://doi.org/10.1016/j.drugpo.2012.07.006  PMID: 22940142 
  62. Sypsa V, Psichogiou M, Paraskevis D, Nikolopoulos G, Tsiara C, Paraskeva D, et al. Rapid decline in hiv incidence among persons who inject drugs during a fast-track combination prevention program after an hiv outbreak in Athens. J Infect Dis. 2017;215(10):1496-505. PMID: 28407106 
  63. Cullen KJ, Hope VD, Croxford S, Shute J, Ncube F, Parry JV. Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey. Epidemiol Infect. 2015;143(7):1398-407.  https://doi.org/10.1017/S0950268814002040  PMID: 25119383 
  64. Memedovic S, Iversen J, Geddes L, Maher L. Australian NSP Survey. National Data Report 2012-2016. Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. National Data Report 2012-2016. Sydney: Kirby Institute; 2017. Available from: https://kirby.unsw.edu.au/sites/default/files/kirby/report/ANSPS_National-Data-Report-2012-2016.pdf
  65. Fotiou A, Kanavou E, Antaraki A, Richardson C, Terzidou M, Kokkevi A, Drug Related Infectious Diseases (DRID) Medical Doctors Group of OKANA. HCV/HIV coinfection among people who inject drugs and enter opioid substitution treatment in Greece: prevalence and correlates. Hepatol Med Policy. 2016;1(1):9.  https://doi.org/10.1186/s41124-016-0017-5  PMID: 30288313 
  66. Hatzakis A, Sypsa V, Paraskevis D, Nikolopoulos G, Tsiara C, Micha K, et al. Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme. Addiction. 2015;110(9):1453-67.  https://doi.org/10.1111/add.12999  PMID: 26032121 
  67. Folch C, Casabona J, Espelt A, Majó X, Meroño M, Gonzalez V, et al. High Prevalence and Incidence of HIV and HCV Among New Injecting Drug Users With a Large Proportion of Migrants--Is Prevention Failing? Subst Use Misuse. 2016;51(2):250-60.  https://doi.org/10.3109/10826084.2015.1092991  PMID: 26820260 
  68. Christensen PB, Krarup HB, Niesters HG, Norder H, Georgsen J. Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol. 2000;16(11):1043-9.  https://doi.org/10.1023/a:1010833917242  PMID: 11421474 
  69. Wiessing L. Epidemiology of HIV and viral hepatitis among people who inject drugs in Europe. Doctoral dissertation. Porto: University of Porto; 2017. Available from: https://repositorio-aberto.up.pt/bitstream/10216/110774/2/252084.docx
  70. Aebi MF, Tiago MM. Prisons and prisoners in Europe 2019: key findings of the SPACE I report. Strasbourg, Lausanne: Council of Europe, Universite de Lausanne; 2020. Available from: http://wp.unil.ch/space/files/2020/04/Key-Findings-2019_200406.pdf
  71. Tresó B, Barcsay E, Tarján A, Horváth G, Dencs A, Hettmann A, et al. Prevalence and correlates of HCV, HVB, and HIV infection among prison inmates and staff, Hungary. J Urban Health. 2012;89(1):108-16.  https://doi.org/10.1007/s11524-011-9626-x  PMID: 22143408 
  72. Unlu A, Tammi T, Hakkarainen P. Drug decriminalization policy literature review: models, implementation and outcomes. Report number: 9/2020. Helsinki: National Institute for Health and Welfare; 2020. Available from: https://www.researchgate.net/publication/342131913_Drug_Decriminalization_Policy_Literature_Review_Models_Implementation_and_Outcomes
  73. Stevens A, Hughes CE, Hulme S, Cassidy R. Depenalization, diversion and decriminalization: A realist review and programme theory of alternatives to criminalization for simple drug possession. Eur J Criminol. 2019;0(0):1477370819887514.  https://doi.org/10.1177/1477370819887514 
  74. Akiyama MJ, Spaulding AC, Rich JD. Flattening the curve for incarcerated populations - Covid-19 in jails and prisons. N Engl J Med. 2020;382(22):2075-7.  https://doi.org/10.1056/NEJMp2005687  PMID: 32240582 
  75. Simpson PL, Butler TG. Covid-19, prison crowding, and release policies. BMJ. 2020;369:m1551.  https://doi.org/10.1136/bmj.m1551  PMID: 32312733 
  76. Aebi MF, Tiago MM. Prisons and prisoners in Europe in pandemic times: an evaluation of the short-term impact of the COVID-19 on prison populations. Strasbourg, Lausanne: Council of Europe, Universite de Lausanne; 2020. Available from: http://wp.unil.ch/space/files/2020/06/Prisons-and-the-COVID-19_200617_FINAL.pdf
  77. Chaudry RV. The Precautionary Principle, public health, and public health nursing. Public Health Nurs. 2008;25(3):261-8.  https://doi.org/10.1111/j.1525-1446.2008.00703.x  PMID: 18477377 
  78. Fischer AJ, Ghelardi G. The precautionary principle, evidence-based medicine, and decision theory in public health evaluation. Front Public Health. 2016;4:107.  https://doi.org/10.3389/fpubh.2016.00107  PMID: 27458575 
  79. Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015;26(Suppl 1):S5-11.  https://doi.org/10.1016/j.drugpo.2014.11.007  PMID: 25727260 
Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 – is the precautionary principle applicable?
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Lucas+Wiessing&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wiessing Lucas</a>, <a href="/search?value1=Eleni+Kalamara&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kalamara Eleni</a>, <a href="/search?value1=Jack+Stone&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Stone Jack</a>, <a href="/search?value1=Peyman+Altan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Altan Peyman</a>, <a href="/search?value1=Luk+Van+Baelen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Van Baelen Luk</a>, <a href="/search?value1=Anastasios+Fotiou&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fotiou Anastasios</a>, <a href="/search?value1=D%E2%80%99Jamila+Garcia&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Garcia D’Jamila</a>, <a href="/search?value1=Joao+Goulao&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Goulao Joao</a>, <a href="/search?value1=Bruno+Guarita&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Guarita Bruno</a>, <a href="/search?value1=Vivian+Hope&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hope Vivian</a>, <a href="/search?value1=Marie+Jauffret-Roustide&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Jauffret-Roustide Marie</a>, <a href="/search?value1=Lina++Jurgelaitien%C4%97&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Jurgelaitienė Lina </a>, <a href="/search?value1=Martin+K%C3%A5berg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kåberg Martin</a>, <a href="/search?value1=Adeeba+Kamarulzaman&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kamarulzaman Adeeba</a>, <a href="/search?value1=Liis+Lemsalu&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lemsalu Liis</a>, <a href="/search?value1=Anda+Kivite-Urtane&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kivite-Urtane Anda</a>, <a href="/search?value1=Branko+Kolari%C4%87&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kolarić Branko</a>, <a href="/search?value1=Linda+Montanari&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Montanari Linda</a>, <a href="/search?value1=Magdalena+Rosi%C5%84ska&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rosińska Magdalena</a>, <a href="/search?value1=Lavinius+Sava&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sava Lavinius</a>, <a href="/search?value1=Ilonka+Horv%C3%A1th&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Horváth Ilonka</a>, <a href="/search?value1=Thomas+Seyler&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Seyler Thomas</a>, <a href="/search?value1=Vana+Sypsa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sypsa Vana</a>, <a href="/search?value1=Anna+Tarj%C3%A1n&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Tarján Anna</a>, <a href="/search?value1=Ioanna+Yiasemi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Yiasemi Ioanna</a>, <a href="/search?value1=Ruth+Zimmermann&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Zimmermann Ruth</a>, <a href="/search?value1=Marica+Ferri&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ferri Marica</a>, <a href="/search?value1=Kate+Dolan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Dolan Kate</a>, <a href="/search?value1=Anneli+Uusk%C3%BCla&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Uusküla Anneli</a>, <a href="/search?value1=Peter+Vickerman&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vickerman Peter</a></span>. Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 – is the precautionary principle applicable?. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(49):pii=2002093. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.49.2002093" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.49.2002093</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 14 Dec 2020;&nbsp;&nbsp; <span class="generated">Accepted</span>: 19 Aug 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.49.2002093
/content/10.2807/1560-7917.ES.2021.26.49.2002093
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error